ÂÜÀòÂÒÂ×

Dr. Burns Naas is an independent consultant providing advice in the areas of nonclinical safety and strategic planning for drug development, and technical due diligence for in-licensing business development opportunities. She was previously Vice President and Head of Nonclinical Safety & Pathobiology at Gilead Sciences and was a Drug Safety Research & Development Therapeutic Area Leader in Oncology and Infectious Disease at Pfizer. Magnolia Toxicology Consulting, LLC provides nonclinical safety strategy development, study planning and monitoring support as well as dossier preparation to meet key milestones including IND/CTA filings, global health authority meetings, and product registration. Dr. Burns Naas experience includes biologics and small molecule development across multiple therapeutic classes.